Anoro Ellipta Special Precautions

The use of Umeclidinium + Vilanterol (Anoro Ellipta) has not been studied in patients with asthma, and is not recommended in this patient population.
Umeclidinium + Vilanterol (Anoro Ellipta) is intended for the maintenance treatment of COPD. It should not be used for the relief of acute symptoms, i.e. as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting bronchodilator. Increasing use of short-acting bronchodilators to relieve symptoms indicates deterioration of control and patients should be reviewed by a physician.
As with other inhalation therapies, administration of Umeclidinium + Vilanterol (Anoro Ellipta) may produce paradoxical bronchospasm that may be life-threatening. Treatment with Umeclidinium + Vilanterol (Anoro Ellipta) should be discontinued if paradoxical bronchospasm occurs and alternative therapy instituted if necessary.
Cardiovascular effects, such as cardiac arrhythmias e.g. atrial fibrillation and tachycardia, maybe seen after the administration of sympathomimetic agents and muscarinic receptor antagonists, including Umeclidinium + Vilanterol (Anoro Ellipta). Therefore, Umeclidinium + Vilanterol (Anoro Ellipta) should be used with caution in patients with severe cardiovascular disease.
Consistent with its antimuscarinic activity, Umeclidinium + Vilanterol (Anoro Ellipta) should be used with caution in patients with narrow-angle glaucoma or urinary retention.
Effects on Ability to Drive and Use Machines: There have been no studies to investigate the effect of Umeclidinium + Vilanterol (Anoro Ellipta) on the ability to perform tasks that require judgement, motor or cognitive skills.